Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study [PDF]
Infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (ABC) are associated with high mortality rates and limited treatment options.
Abbo, Lilian M. +33 more
core +1 more source
Avanços na terapia antimicrobiana em infecções causadas pela espécie Acinetobacter baumannii [PDF]
, 2019 Acinetobacter baumannii is often associated to healthcare-associated infections, representing a serious public health problem, as it increases the risk of death in critically ill and immunocompromised patients.
Josiane Patrícia Nogueira da Cunha
core
Treatment Strategies of Colistin Resistance Acinetobacter baumannii Infections
AntibioticsAcinetobacter baumannii has emerged as a pressing challenge in clinical practice, mainly due to the development of resistance to multiple antibiotics, including colistin, one of the last-resort treatments.
Andria Papazachariou +5 more
doaj +1 more source
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions. [PDF]
BACKGROUND: Carbapenem-resistant Acinetobacter baumannii (CRAb) is 1 of the most problematic antimicrobial-resistant bacteria. We sought to elucidate the international epidemiology and clinical impact of CRAb.
Alenazi, Thamer +41 more
core +1 more source
Comparative analysis of Acinetobacter baumannii bloodstream isolates from children and adults in southern China [PDF]
IntroductionAcinetobacter baumannii (A. baumannii) is a major pathogen responsible for hospital-acquired bloodstream infections, with multidrug-resistant (MDR) strains posing severe therapeutic challenges.
Cheng Li +10 more
core +1 more source
Multidrug resistance Acinetobacter species in ventilator associated pneumonia patients in MICU [PDF]
Background: Ventilator associated pneumonia (VAP) is defined as pneumonia that develops 48-72 hours after endotracheal intubation and is characterized by the presence of a new or progressive infiltrate, symptoms of systemic infection, respiratory ...
Harbade, Mangala S. +3 more
core +2 more sources
Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs
Emerging Infectious DiseasesThe US Food and Drug Administration recognizes the unmet medical need for antibacterial drugs to treat serious bacterial diseases caused by resistant pathogens for which effective therapies are limited or lacking.
Mayurika Ghosh +11 more
doaj +1 more source
Resistance of Gram-Negative Bacteria to Eravacycline: A Systematic Review of Data from In Vitro Studies [PDF]
Introduction: Eravacycline is a new fluorocycline antibiotic with a broad spectrum of antimicrobial activity approved for the treatment of patients with complicated intra-abdominal infections.
Falagas, Matthew E. +4 more
core +2 more sources
Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii
Frontiers in Cellular and Infection MicrobiologyPatients with severe carbapenem-resistant Acinetobacter baumannii (CRAB) infections currently face significant treatment challenges. When patients display signs of infection and the clinical suspicion of CRAB infections is high, appropriate treatment ...
Siqin Zhang +4 more
doaj +1 more source
Cefepime-Enmetazobactam: a novel β-Lactam/β-Lactamase inhibitor combination for complicated urinary tract infections [PDF]
Complicated urinary tract infections (cUTIs) represent a significant global health challenge, particularly with the rising prevalence of extended-spectrum β-lactamase (ESBL)-producing pathogens.
Balaji, Vikram +4 more
core +2 more sources